Guyer William sold $419K of CORT

Guyer William (Chief Development Officer) sold 3,700 shares of CORCEPT THERAPEUTICS INC (CORT) at $113.12 ($0.42M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guyer William
Published Aug 6, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, price, and post-transaction holdings; there is no accompanying corporate event that would reset valuation assumptions.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-scheduled liquidity needs; without additional context, the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-06 after-hours; transaction dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported as an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics Form 4 shows insider William Guyer sold 3,700 shares at $113.1248 on 2026-08-04 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is typically sentiment-driven and short-lived.

Evidence & confidence

The filing is a scheduled 10b5-1 open-market sale, and the article provides no accompanying company-specific news (earnings, guidance, trials, deals, or enforcement).

Market effects

No clear sector read-through because the disclosure lacks new clinical, regulatory, or product information.

None indicated; this is a single-company insider transaction.

None indicated.

Counterpoint

A 10b5-1 sale can be purely mechanical and may not signal reduced confidence; traders should avoid over-weighting it versus fundamentals.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • William Guyer

    Chief Development Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.